Ilya Rachman
Algemeen Directeur bij IMMIX BIOPHARMA, INC.
Vermogen: 2 M $ op 31-05-2024
Profiel
Ilya Rachman is the founder of Immix Biopharma, Inc., where he holds the title of Chairman & Chief Executive Officer since 2012.
He is also the founder of Nexcella, Inc., where he currently serves as the Executive Chairman.
Dr. Rachman has an MBA from the University of California, Los Angeles, and has completed graduate and doctorate degrees from the University of Illinois.
He also holds an undergraduate degree from the University of Iowa.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
IMMIX BIOPHARMA, INC.
4.30% | 11-06-2024 | 1 136 259 ( 4.30% ) | 2 M $ | 31-05-2024 |
Actieve functies van Ilya Rachman
| Bedrijven | Functie | Begin |
|---|---|---|
| IMMIX BIOPHARMA, INC. | Algemeen Directeur | 01-01-2012 |
Nexcella, Inc.
 Nexcella, Inc. BiotechnologyHealth Technology Part of Immix Biopharma, Inc., Nexcella, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles, CA. The company is engaged in the discovery and development of novel cell therapies for oncology and other indications. Nexcella's lead candidate, next generation bcma-targeted car-t nxc-201, has produced high response rates in relapsed/refractory al amyloidosis and relapsed/refractory multiple myeloma, and has been awarded orphan drug designation by the FDA in both indications. The company's n-genius platform allows for the discovery, development, and manufacture of cutting-edge cell therapies for patients in need. Expansion into autoimmune indications is planned. | Voorzitter | - |
Opleiding van Ilya Rachman
| University of Illinois | Doctorate Degree |
| University of Iowa | Undergraduate Degree |
| University of California, Los Angeles | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| IMMIX BIOPHARMA, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Nexcella, Inc.
Nexcella, Inc. BiotechnologyHealth Technology Part of Immix Biopharma, Inc., Nexcella, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles, CA. The company is engaged in the discovery and development of novel cell therapies for oncology and other indications. Nexcella's lead candidate, next generation bcma-targeted car-t nxc-201, has produced high response rates in relapsed/refractory al amyloidosis and relapsed/refractory multiple myeloma, and has been awarded orphan drug designation by the FDA in both indications. The company's n-genius platform allows for the discovery, development, and manufacture of cutting-edge cell therapies for patients in need. Expansion into autoimmune indications is planned. | Health Technology |
